$160 Million is the total value of Tamarack Advisers, LP's 31 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 137.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDRX | Buy | ALLSCRIPTS HEALTHCARE SOLUTI | $12,236,000 | +56.7% | 965,000 | +26.1% | 7.64% | +38.4% |
| NKTR | New | NEKTAR THERAPEUTICS | $11,735,000 | – | 500,000 | +100.0% | 7.33% | – |
| GILD | Buy | GILEAD SCIENCES INC | $10,188,000 | +42.3% | 150,000 | +50.0% | 6.36% | +25.7% |
| Buy | NOVOCURE LTD | $8,025,000 | +23.9% | 990,750 | +20.1% | 5.01% | +9.5% | |
| WBA | New | WALGREENS BOOTS ALLIANCE INC | $7,475,000 | – | 90,000 | +100.0% | 4.67% | – |
| HCA | New | HCA HEALTHCARE INC | $7,119,000 | – | 80,000 | +100.0% | 4.45% | – |
| STE | Buy | STERIS PLC | $6,817,000 | +60.6% | 98,150 | +55.8% | 4.26% | +41.8% |
| BKD | New | BROOKDALE SENIOR LIVING INClisted option | $6,805,000 | – | 503,000 | +100.0% | 4.25% | – |
| OBLN | Buy | OBALON THERAPEUTICS INC | $6,050,000 | +21.5% | 565,912 | +0.6% | 3.78% | +7.3% |
| BSX | Buy | BOSTON SCIENTIFIC CORP | $4,974,000 | +683.3% | 200,000 | +8990.9% | 3.11% | +592.2% |
| ALKS | Buy | ALKERMES PLC | $4,680,000 | +8.0% | 80,000 | +2.6% | 2.92% | -4.6% |
| CORI | Buy | CORIUM INTERNATIONAL INC | $4,443,000 | +48.4% | 1,063,000 | +44.2% | 2.78% | +31.1% |
| LNTH | New | LANTHEUS HOLDINGS INC | $3,634,000 | – | 290,700 | +100.0% | 2.27% | – |
| SRCL | New | STERICYCLE INC | $2,470,000 | – | 29,800 | +100.0% | 1.54% | – |
| OPHT | New | OPHTHOTECH CORP | $1,724,000 | – | 471,149 | +100.0% | 1.08% | – |
| AKRXQ | New | AKORN INC | $1,709,000 | – | 70,969 | +100.0% | 1.07% | – |
| NVRO | New | NEVRO CORP | $1,602,000 | – | 17,100 | +100.0% | 1.00% | – |
| RCM | New | R1 RCM INC | $795,000 | – | 257,400 | +100.0% | 0.50% | – |
| ENTL | New | ENTELLUS MEDICAL INC | $633,000 | – | 45,837 | +100.0% | 0.40% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERADIGM ORD | 32 | Q3 2023 | 13.9% |
| STREAMLINE HEALTH SOLUTIONS ORD | 30 | Q3 2023 | 4.0% |
| ATRICURE ORD | 29 | Q3 2023 | 7.6% |
| PACIRA PHARMACEUTICALS INC | 27 | Q1 2023 | 12.1% |
| LANTHEUS HOLDINGS ORD | 25 | Q4 2022 | 9.6% |
| MEDTRONIC PLC | 21 | Q1 2022 | 12.7% |
| RIGEL PHARMACEUTICALS ORD | 21 | Q2 2023 | 8.0% |
| BIO RAD LABORATORIES CL A ORD | 19 | Q2 2023 | 10.0% |
| HOLOGIC INC | 17 | Q1 2022 | 6.5% |
| SPY US 10/21/16 P210 | 17 | Q3 2023 | 41.5% |
View Tamarack Advisers, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTIONS INC. | June 22, 2023 | 5,514,515 | 9.4% |
| IVERIC bio, Inc. | February 16, 2021 | 850,000 | 0.1% |
| Correvio Pharma Corp. | February 14, 2020 | 2,500,000 | 4.9% |
| OBALON THERAPEUTICS INC | February 14, 2020 | ? | ? |
| Correvio Pharma Corp. | February 15, 2019 | ? | ? |
| Corium International, Inc. | February 15, 2017 | 737,242 | 3.3% |
| ENDOLOGIX INC /DE/Sold out | February 15, 2017 | 0 | 0.0% |
| Imprivata IncSold out | February 15, 2017 | 0 | 0.0% |
View Tamarack Advisers, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-16 |
| 13F-HR | 2023-08-10 |
| SC 13D/A | 2023-06-22 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-01 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-11 |
View Tamarack Advisers, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.